Russian Heart Failure Journal 2009year Optimization of the individualized approach to management of elderly patients with CHF in the outpatient conditions

To access this material please log in or register

Register Authorize

Optimization of the individualized approach to management of elderly patients with CHF in the outpatient conditions

Larina V. N., Bart B. Ya.



Urgency. ACEI take the leading place in the treatment of patients with CHF. Prognosis of elderly patients with CHF also benefits from the use of ACEI. Aim. Optimizing the individualized approach and complex therapy in elderly patients with CHF in the outpatient conditions. Materials and methods. Study enrolled 53 patients with II-IV FC CHF aged from 60 to 85 years. Evaluation of patients included echoCG, laboratory tests, 6-min walking test, and determination of quality of life at baseline and during the fosinopril treatment. In addition, clinical status of patients was evaluated using the clinical condition scale (CCS) and the presence and severity of anxiety and depression. Results. Inclusion of the ACEI fosinopril into the complex therapy improved the clinical condition and quality of life in patients, reduced signs of depression and anxiety, although patients did not receive antidepressants. The therapy was well tolerated in the vast majority of patients. Serum potassium did not increase in the course of treatment. The administered therapy was associated with statistically significant decreases in diastolic BP and heart rate and statistically non-significant decreases in systolic and pulse BP. Data of echoCG examination showed decreases in mean pulmonary artery pressure and LV end-diastolic pressure. Therefore the high efficacy and safety of fosinopril substantiate recommendation of a broader use of the drug in the complex therapy for CHF in elderly patients in the outpatient conditions.
  1. Alexander KP, Biswas MS. Heart failure and the elderly: disease diversity, data, and delivery of care. Am Heart J. 2003; 146 (2):194‑196.
  2. Masoudi FA, Havranek EP, Wolfe P et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003; 146 (2):250‑257.
  3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23):1429–1435.
  4. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327 (10):669‑677.
  5. Мареев В. Ю. Фармакоэкономическая оценка использования иАПФ в амбулаторном лечении больных с сердечной недостаточностью (ФАСОН). Журнал Сердечная Недостаточность. 2002; 3 (1):38–39.
  6. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения сердечной недостаточности. – М.: Materia Medica, 2000. – 266с.
  7. Rector TS, Kubo SK, Cohn JN. Patient’s self-assessment of their congestive heart failure, II: content, reliability and validity of a new measure, The Minnesota Living with Heart Failure Questionnaire. Heart Failure. 1987; 3:198‑209.
  8. Guyatt GH, Thompson PJ, Berman LB et al. How should we measure function in patients with chronic heart and lung disease? J Chronic Dis. 1985; 38 (6):517‑524.
  9. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67 (6):361‑370.
  10. Levey AS, Coresh J, Greene T et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53 (4):766‑772.
  11. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130 (6):461‑470.
  12. National Kidney Foundation KD: Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis. 2002; 39 (Suppl 1):S1‑S266.
  13. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005; 26 (11):1115–1140.
  14. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007; 8 (1):4–41.
  15. Jaarsma T. Heart failure management programs: how far should we go? Eur J Heart Fail. 2003; 5 (3):215‑216.
  16. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991; 325 (5):293‑302.
  17. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342 (8875):821‑828.
  18. Flather M, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000; 355 (9215):1575–1581.
  19. Masoudi FA, Rathore SS, Wang Y et al. National patterns of use and effectiveness of angiotensin – converting enzyme inhibitors in older patients with heart failure and left ventricular dysfunction. Circulation. 2004; 110 (6):724‑731.
  20. Pilote L, Abrahamowicz M, Eisenberg M et al. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ. 2008; 178 (10):1303–1311.
  21. Linné AB, Liedholm H, Israelsson B. Effects of systematic education on heart failure patients’ knowledge after 6 months. A randomised, controlled trial. Eur J Heart Fail. 1999; 1 (3):219‑227.
  22. Гиляревский С. Р., Орлов В. А., Середенина Е. М. Самоконтроль и самолечение больных с хронической сердечной недостаточностью: границы эффективности и безопасности. Журнал Сердечная Недостаточность. 2002; 3 (5):237‑244.
  23. van der Wal MH, Jaarsma T, Moser DK et al. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J. 2006; 27 (4):434‑440.
  24. Brown EJ Jr, Chew PH, MacLean A et al. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. The Fosinopril Heart Failure Study Group. Am J Cardiol. 1995; 75 (8):596‑600.
  25. Zannad F, Chati Z, Guest M, Plat F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators. Am Heart J. 1998; 136 (4 Pt 1):672‑680.
  26. Jaarsma T, Van Der Wal MH, Hogenhuis J et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail. 2004; 6 (2):227‑233.
  27. Атрощенко Е. С. Пациент с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2007; 8 (6):297‑300.
  28. Чазов Е. И. Пути снижения смертности от сердечно-сосудистых заболеваний. Тер. Архив. 2008; 80 (8):11–16.
  29. Freudenberger R, Cahn SC, Skotzko C. Influence of age, gender, and race on depression in heart failure patients. J Am Coll Cardiol. 2004; 44 (11):2254–2255.
  30. Чазов Е. И. Депрессия как фактор развития и прогрессирования сердечно-сосудистых заболеваний. Журнал Сердечная Недостаточность. 2003; 4 (1):6–8.
  31. Freedland KE, Carney RM, Rich MW et al. Depression in elderly patients with congestive heart failure. J Geriatr Psychiatry. 1991; 24 (1):59–71.
  32. Friedmann E, Thomas SA, Liu F et al. Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J. 2006 Nov; 152 (5):940.e1-8.
  33. Lecrubier Y. The burden of depression and anxiety in general medicine. J Clin Psychiatry. 2001; 62 (Suppl 8):4–9.
  34. Faggiano P, D’Aloia A, Gualeni A et al. The 6 minute walking test in chronic heart failure: indications, interpretation and limitations from a review of the literature. Eur J Heart Fail. 2004; 6 (6):687‑691.
  35. Гиляревский С. Р., Орлов В. А., Хамаганова Л. К. и др. Влияние терапевтического обучения больных с хронической сердечной недостаточностью на качество их жизни и потребность в ранних повторных госпитализациях. Журнал Сердечная Недостаточность. 2001; 2 (4):187‑190.
  36. Власова А. В., Лямина Н. П. Качество жизни и факторы его определяющие, у больных с хронической сердечной недостаточностью, развившейся после перенесенного инфаркта миокарда. Журнал Сердечная Недостаточность. 2002; 3 (5):226‑228.
  37. Крюков Н. Н., Качковский М. А. Влияние сердечной недостаточности на качество жизни больных инфарктом миокарда. Журнал Сердечная Недостаточность. 2005; 5 (4):169‑171.
  38. Ezekowitz JA, Bakal JA, Kaul P et al. Acute Heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. Eur J Heart Fail. 2008; 10 (3):308‑314.
  39. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the U. S., 1979 to 2004. J Am Coll Cardiol. 2008; 52 (6):428‑434.
  40. Гендлин Г. Е., Борисовская С. В., Эттингер О. А. и др. Лечение ингибиторами ангиотензинпревращающего фермента больных с преддиализной хронической почечной недостаточностью. Consilium medicum. 2007; 9: (11) 3–7.
  41. Echemann M, Zannad F, Briancon S et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J. 2000; 139 (4):624‑631.
  42. Oxenham H, Sharpe N. Cardiovascular aging and heart failure. Eur J Heart Fail. 2003; 5 (4):427‑434.
  43. Levine TB, Levine AB, Bolenbaugh J, Green PR. Reversal of heart failure remodeling with age. Am J Geriatr Cardiol. 2002; 11 (5):299‑304.
  44. Кореннова О. Ю., Петренко А. В., Петренко М. А. и др. Клинико-экономическая эффективность ингибиторов ангиотензинпревращающего фермента у пациентов с артериальной гипертонией и ишемической болезнью сердца. Кардиология. 2008; 48 (6): 40–43.
  45. Хозяинова Н. Ю., Царева В. М., Сухарукова О. В. и др. Роль фозиноприла в профилактике хронической сердечной недостаточности у больных артериальной гипертонией. Журнал Сердечная Недостаточность. 2005; 6 (4):166‑168.

To access this material please log in or register

Register Authorize
Ru En